Press releases

Lipum AB (publ) announces that the company, together with the Norwegian company Age Labs AS, has received a grant from Eurostars. The companies will establish...
Lipum AB (publ) ("Lipum") announces its Nomination Committee for the Annual General Meeting 2025. In accordance with the decision at the Annual...
Lipum AB (publ), a Swedish biopharmaceutical company focusing on innovative treatments for chronic inflammatory diseases, presented positive findings from...
Lipum AB (publ) has published the interim report Q3 for the period July-September 2024. Below is a summary, a complete report (only in Swedish) is available...
Lipum AB (publ) announces that the eighth and thus final patient with rheumatoid arthritis (RA) has been recruited and dosed with SOL-116 or placebo in...
Lipum AB (publ) recruits Peter Hovstadius as the new Chief Medical Officer (CMO). Peter Hovstadius is a specialist in clinical pharmacology with a PhD...
Lipum AB (publ), a clinical stage biopharmaceutical company developing the drug candidate SOL-116 focused on chronic inflammatory diseases, today announced...
Lipum AB (publ) has published the interim report Q2 for the period January-June 2024. Below is a summary, a complete report (only in Swedish) is available...
Lipum AB (publ) received in August 2018 a M€ 2.2 / MSEK 23 grant from the European Commission innovation program Horizon 2020. The successful project...
Lipum AB (publ) announces that the multiple dose part of the phase I clinical study is completed. Eight healthy subjects have received four doses 28 days...

Investor relations